Caris Life Sciences, Inc.
CAI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.52 | -1.31 | 0.00 | -1.83 |
| FCF Yield | -3.56% | -4.19% | -4.60% | 11.45% |
| EV / EBITDA | -40.94 | -27.96 | -29.68 | 10.88 |
| Quality | ||||
| ROIC | -105.17% | -98.47% | -49.52% | 5.49% |
| Gross Margin | 43.37% | 29.17% | 30.96% | 62.64% |
| Cash Conversion Ratio | 0.87 | 0.81 | 0.89 | 9.99 |
| Growth | ||||
| Revenue 3-Year CAGR | 16.84% | 1.36% | -14.70% | -12.04% |
| Free Cash Flow Growth | 15.00% | 9.01% | 0.00% | 188.37% |
| Safety | ||||
| Net Debt / EBITDA | -1.97 | -0.62 | -0.67 | 8.39 |
| Interest Coverage | -5.14 | -10.11 | -11.83 | 2.26 |
| Efficiency | ||||
| Inventory Turnover | 5.90 | 4.43 | 3.80 | 0.00 |
| Cash Conversion Cycle | 96.55 | 103.50 | 97.07 | 166.96 |